Anacor Pharma Q3 Beats on Revenues, Misses on Net

Anacor Pharmaceuticals  (NASDAQ: ANAC  ) is still in need of some bottom-line healing, if its Q3 results are any indication. The company said it posted $3.6 million in total revenues for the quarter, which was an improvement over the $2.5 million in the same three-month period the previous year. However, net loss widened over that span of time to $16.8 million ($0.41 per diluted share) from the year-ago Q3's shortfall of $14.4 million ($0.46).

On average, analysts had expected revenue of $2.7 million and a per-share loss of $0.39.  

The company provided selected forward guidance for the entirety of fiscal 2013. It expects to end the year with at least $160 million in cash, cash equivalents, short-term investments, and restricted investments, which should "be sufficient to meet our anticipated operating requirements for at least the next twelve months." These funds include the monies that are to be paid to the company from last month's arbitration proceeding against Valeant Pharmaceuticals


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2718340, ~/Articles/ArticleHandler.aspx, 11/21/2014 10:30:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement